Search research articles
Contact Us
Filters
Showing results (561-570 of 652) with videos related to
Page
of 66
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group
Meletios A Dimopoulos, Evangelos Terpos, Asher Chanan-Khan, et al.
American Journal of Hematology
|
April 24, 2014
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients
Eirini Katodritou, Evangelos Terpos, Argiris S Symeonidis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
Jesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
The New England Journal of Medicine
|
May 11, 2012
Continuous lenalidomide treatment for newly diagnosed multiple myeloma
Antonio Palumbo, Roman Hajek, Michel Delforge, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
The Lancet. Oncology
|
April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Nature Communications
|
February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia
Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 4, 2021
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Maria-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Haematologica
|
December 15, 2015
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
Meletios A Dimopoulos, Matthew C Cheung, Murielle Roussel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis
Eli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
Page
of 66
Search research articles
Search
Showing results (561-570 of 652) with videos related to
Sort By:
Page
of 66
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group
Meletios A Dimopoulos, Evangelos Terpos, Asher Chanan-Khan, et al.
American Journal of Hematology
|
April 24, 2014
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients
Eirini Katodritou, Evangelos Terpos, Argiris S Symeonidis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
Jesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
The New England Journal of Medicine
|
May 11, 2012
Continuous lenalidomide treatment for newly diagnosed multiple myeloma
Antonio Palumbo, Roman Hajek, Michel Delforge, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 13, 2025
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, et al.
The Lancet. Oncology
|
April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Nature Communications
|
February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia
Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 4, 2021
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Maria-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Haematologica
|
December 15, 2015
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
Meletios A Dimopoulos, Matthew C Cheung, Murielle Roussel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2022
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis
Eli Muchtar, Angela Dispenzieri, Brendan Wisniowski, et al.
Page
of 66